EP2020248A1 - System zur behandlung von herzkrankheiten - Google Patents

System zur behandlung von herzkrankheiten Download PDF

Info

Publication number
EP2020248A1
EP2020248A1 EP04822649A EP04822649A EP2020248A1 EP 2020248 A1 EP2020248 A1 EP 2020248A1 EP 04822649 A EP04822649 A EP 04822649A EP 04822649 A EP04822649 A EP 04822649A EP 2020248 A1 EP2020248 A1 EP 2020248A1
Authority
EP
European Patent Office
Prior art keywords
value
target
atrial pressure
pressure value
pumping ability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP04822649A
Other languages
English (en)
French (fr)
Other versions
EP2020248B1 (de
EP2020248A4 (de
Inventor
K. Uemura
A. Kamiya
Masaru Sugimachi
Kenji Sunagawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Health Sciences Foundation
Original Assignee
Japan Health Sciences Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Health Sciences Foundation filed Critical Japan Health Sciences Foundation
Publication of EP2020248A1 publication Critical patent/EP2020248A1/de
Publication of EP2020248A4 publication Critical patent/EP2020248A4/de
Application granted granted Critical
Publication of EP2020248B1 publication Critical patent/EP2020248B1/de
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
    • A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/02028—Determining haemodynamic parameters not otherwise provided for, e.g. cardiac contractility or left ventricular ejection fraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/021—Measuring pressure in heart or blood vessels
    • A61B5/0215—Measuring pressure in heart or blood vessels by means inserted into the body
    • A61B5/02158—Measuring pressure in heart or blood vessels by means inserted into the body provided with two or more sensor elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/026—Measuring blood flow
    • A61B5/029—Measuring or recording blood output from the heart, e.g. minute volume
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/30—Blood pressure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body

Definitions

  • the present invention relates to a cardiac disease treatment system. More particularly, the present invention provides a system for treating cardiac diseases by accurately diagnosing the functional causes of abnormalities related to cardiac diseases and then automatically administering drugs according to the diagnosis.
  • Cardiac diseases are effectively treated by an emergency care by specialized cardiologists during the acute phase. However, only 3% of all physicians are specialized in treating cardiac diseases, which is not sufficient.
  • a cardiac disease treatment system disclosed in Tokuhyou 2000-507129 that automatically adjusts the intravenous administration of cardiovascular drugs.
  • the system disclosed in Tokuhyou 2000-507129 is used to automatically control the intravenous administration of cardiovascular drugs (e.g., vasodilators) to a patient for stabilization of drug concentration in blood, for example, during anesthesia.
  • cardiovascular drugs e.g., vasodilators
  • the system described in Tokuhyou 2000-507129 aims at control of drug concentration in blood or the pharmacokinetics of drugs in patients, but not at improvement of the hemodynamic parameters or the organ systems of patients. Also, the system is applicable only to patients under anesthesia. Therefore the system does not solve the above problems.
  • one object of the present invention is to provide a cardiac disease treatment system that analyzes the hemodynamics of a patient, specifies the functional cause of abnormalities related to cardiac diseases, and automatically administers drugs for treating cardiac diseases according to the diagnosis.
  • the invention defined in Claim 1 relates to a cardiac disease treatment system comprising: an input means (2) inputting a cardiac output value, a left atrial pressure value, and/or a right atrial pressure value of a patient; a first calculation means (31) calculating a pumping ability value of the left heart or the right heart from the cardiac output value, the left atrial pressure value, and the right atrial pressure value which are input from the input means; a first comparison means (41) comparing calculated values of pumping ability of the left heart and/or the right heart and target pumping ability values; and a first dosing means (51) administering drugs to the patient according to comparison results in the first comparison means (41).
  • the invention defined in Claim 2 relates to a cardiac disease treatment system wherein the first calculation means (31) uses equation 1 and/or equation 2 to calculate the pumping ability value of the left heart and/or the right heart from the cardiac output value, the left atrial pressure value, and/or the right atrial pressure value input by the input means (2).
  • cardiac output value ( pumping ability value of the heart ) ⁇ Log ( left atrial pressure value - A ) + B (where A and B are constants)
  • cardiac output value pumping ability value of the right heart ⁇ Log ( ( right atrial pressure value ) - C ) + D (where C and D are constants)
  • the invention defined in Claim 3 relates to a cardiac disease treatment system further comprising a first target decision means (71) calculating a target pumping ability value of the left heart and/or the right heart as the target pumping ability value from the target cardiac output value, the target left atrial pressure value, and/or the target right atrial pressure value.
  • the invention defined in Claim 4 relates to a cardiac disease treatment system wherein the first target decision means (71) uses equation 3 and equation 4 to calculate the pumping ability value of the left heart and/or the right heart from the target cardiac output value, the target left atrial pressure value, and/or the target right atrial pressure value.
  • / Log ( ( target left atrial pressure value ) - A ) + B ( target pumping ability value of the right heart ) target cardiac output value (where A and B are constants)
  • / Log ( ( target right atrial pressure value ) - C ) + D ( target pumping ability value of the right heart ) target cardiac output value (where C and D are constants)
  • the invention defined in Claim 5 relates to a cardiac disease treatment system comprising: an input means (2) inputting a cardiac output value, a left atrial pressure value, and a right atrial pressure value of a patient; a second calculation means (32) calculating an effective circulating blood volume value from the cardiac output value, the left atrial pressure value, and the right atrial pressure value which are input from the input means (2); a second comparison means (42) comparing the effective circulating blood volume value calculated by the second calculation means (32) and a target effective circulating blood volume value; and a second dosing means (52) administering drugs to the patient according to the comparison result in the second comparison means (42).
  • the invention defined in Claim 6 relates to a cardiac disease treatment system wherein the second comparison means (32) uses equation 5 to calculate the effective circulating blood volume value from the cardiac output value, the left atrial pressure value, and the right atrial pressure value input by the input means (2).
  • cardiac output value 1 E effective circulating blood volume value - F right atrial pressure value - G left atrial pressure value ⁇ where all of E , F , and G are constants
  • the invention defined in Claim 7 relates to a cardiac disease treatment system further comprising a second target decision means (72) calculating a target effective circulating blood volume value from the target cardiac output value, the target left atrial pressure value, and the target right atrial pressure value.
  • the invention defined in Claim 9 relates to a cardiac disease treatment system comprising: an input means (2) inputting a cardiac output value, a right atrial pressure value, and a arterial blood pressure value of a patient; a third calculation means (33) calculating a vascular resistance value from the cardiac output value, the right atrial pressure value, and the arterial blood pressure value which are input from the input means (2); a third comparison means (43) comparing the vascular resistance value calculated by the third calculation means (33) and a target vascular resistance value; a third dosing means (53) administering drugs to the patient according to the comparison result in the third comparison means (43).
  • the invention defined in Claim 11 relates to a cardiac disease treatment system further comprising a third target decision means (73) calculating a target vascular resistance value from the target cardiac output value, the target right atrial pressure value, and/or the target right atrial pressure value.
  • the invention defined in Claim 13 relates to a cardiac disease treatment system that is a combination of two or three of the systems defined in claims 1, 5, and 9.
  • the invention defined in Claim 14 relates to a cardiac disease treatment system further comprises a display means (6) continuously displaying each of the calculated values calculated by the calculation means (31), (32), and (33) in chronological order.
  • the invention defined in Claim 15 relates to a cardiac disease treatment system wherein the cardiac output value is measured by a Swan-Ganz catheter or calculated from a diastolic time constant of arterial blood pressure waveform.
  • the invention defined in Claim 16 relates to a cardiac disease treatment system wherein the left atrial pressure value is directly measured by a catheter or continuously estimated from diastolic pressure values of pulmonary capillary wedge pressure or pulmonary arterial pressure which are measured by a Swan-Ganz catheter.
  • a cardiac disease treatment system calculates a pumping ability value of the left heart or the right heart from cardiac output and left atrial pressure and/or right atrial pressure. The cardiac disease treatment system then compares the calculated pumping ability value of the left heart and/or the right heart with target pumping ability values and diagnoses the abnormalities in pumping ability to administer drugs according to the diagnosis.
  • the cardiac treatment system uses Equation 1 and Equation 2 in order to calculate pumping ability more minutely and clearly. Adjustment of constants A to D allows the pumping ability values calculated for various patients to be corrected.
  • Correction of the calculated pumping ability values for each patient enables more accurate calculation of the pumping ability for more accurate treatment to each patient.
  • the cardiac treatment system uses a target cardiac output value, a target left atrial pressure value and/or a target right atrial pressure value to calculate target pumping ability values including a target pumping ability value of the left heart and/or a target pumping ability value of the right heart in a simple way.
  • the cardiac treatment system uses Equation 3 and Equation 4 to more appropriately calculate the target pumping ability values.
  • the cardiac treatment system calculates an effective circulating blood volume value of the patient from cardiac output, left atrial pressure, and right atrial pressure of a patient. The cardiac treatment system then compares the calculated effective circulating blood volume value with the target effective circulating blood volume value to administer drugs according to the comparison result.
  • the administration according to the comparison between the calculated effective circulating blood volume value and the target effective circulating blood volume value secures that the abnormal effective circulating blood volume is corrected to be in a normal state during a treatment to the patient.
  • the cardiac disease treatment system uses Equation 5 to calculate the effective circulating blood volume more minutely and clearly. Adjustment of constants E to G allows the effective circulating blood volume values calculated for various patients to be corrected.
  • Correction of the calculated effective circulating blood volume value for each patient enables more accurate calculation of the effective circulating blood volume for more accurate treatment to each patient.
  • the cardiac disease treatment system calculates the target effective circulating blood volume value from the target cardiac output value, the target left atrial pressure value, and the target right atrial pressure value in a simple way.
  • the cardiac disease treatment system uses Equation 6 to more appropriately calculate the target effective circulating blood volume value.
  • the cardiac disease treatment system calculates a vascular resistance value from input values of cardiac output, right atrial pressure, and arterial blood pressure of a patient and compares the calculated vascular resistance value and the target vascular resistance value to administer drugs according to the comparison result.
  • the administration of drugs according to the comparison result between the calculated vascular resistance value and the target vascular resistance value secures that the abnormal vascular resistance value is accurately corrected to be in a normal range.
  • the cardiac disease treatment system uses Equation 7 to calculate the vascular resistance value more minutely and clearly.
  • Constant H in equation 7 is employed for correcting the non-linearity of vascular resistance. Adjustment of constant H enables normal operation of the system to be maintained even in a subject with a highly non-linear vascular resistance.
  • the cardiac disease treatment system calculates the target vascular resistance value from the target cardiac output value, the target right atrial pressure value, the target arterial blood pressure value in a simple way.
  • the cardiac disease treatment system uses Equation 8 to more appropriately calculate the target vascular resistance value.
  • the cardiac disease treatment system calculates the pumping ability value of the left heart and/or the right heart, the effective circulating blood volume value, and the vascular resistance value from cardiac output, right atrial pressure, left atrial pressure, and arterial blood pressure, and compares the calculated values and the target values to administer drugs according to the comparison results.
  • the cardiac disease treatment system continuously displays each value of pumping ability of the left heart and/or the right heart, effective circulating blood volume, and vascular resistance. This prevents a chronological change in patient conditions from being ignored and enables reliable diagnosis on a patient.
  • the cardiac disease treatment system also displays the effect of drug administration on patient conditions.
  • cardiac output is measured by a Swan-Ganz catheter or calculated from a diastolic time constant of arterial blood pressure waveform whereas left atrial pressure is directly measured by a catheter or continuously estimated from diastolic pressure values of pulmonary capillary wedge pressure or pulmonary arterial pressure which are measured by a Swan-Ganz catheter. This results in a highly accurate cardiac disease treatment system.
  • Fig. 1 is a block diagram schematically showing a cardiac disease treatment system according to the present invention.
  • Fig. 2 is a schematic view of a heart.
  • Cardiac disease treatment system (1) in the present invention utilizes cardiac output (CO) values, left atrial pressure (Pla) values, and right atrial pressure (Pra) values shown in Fig. 2 , as well as arterial blood pressure (AP) values (not shown).
  • CO cardiac output
  • Pr left atrial pressure
  • Pra right atrial pressure
  • AP arterial blood pressure
  • Cardiac disease treatment system (1) is used to determine the functional cause of abnormality in the cardiovascular system based on a hemodynamic abnormality (e.g., reduction in CO (peripheral circulatory failure), elevation in Pla (pulmonary congestion), and arterial blood pressure (increase and decrease)) to administer appropriate therapeutic agents.
  • a hemodynamic abnormality e.g., reduction in CO (peripheral circulatory failure), elevation in Pla (pulmonary congestion), and arterial blood pressure (increase and decrease)
  • Cardiac disease treatment system (1) includes an input means (2), a calculation means (3), a comparison means (4), a dosing means (5), a display means (6), and a target decision means (7).
  • Input means (2) inputs measurement values (numeric data) of the hemodynamics in a patient to calculation means (3) (described below). Input means (2) is configured to input measurement values of AP, CO, Pra, and Pla.
  • Input means (2) may be any configuration that is capable of inputting numeral data to calculation means (3).
  • Input means (2) may be an input device (e.g., keyboard) that allows a person using cardiac disease treatment system (1) to input actual measurement values, or a measurement device that measures the hemodynamics in a patient and inputs the values directly to calculation means (3), though not limited to these. If cardiac disease treatment system (1) is constantly connected to a patient for drug administration in order to diagnose abnormalities related to cardiac diseases, cardiac disease treatment system (1) is preferably configured to allow the measurement values of the hemodynamics in a patient to be directly input to calculation means (3).
  • the hemodynamics numeric data (AP value and CO value, as well as Pra and Pla values) input by input means (2) are respectively obtained using a conventional measurement device.
  • the measurement device may be a catheter placed in a peripheral artery (e.g., radial artery) for measuring AP and a Swan-Ganz catheter for measuring CO, Pla, and Pra, though not limited to these.
  • Cardiac disease treatment system (1) continuously obtains these measurement values and uses them for a continuous diagnosis of a patient.
  • it is known to be impossible to continuously measure Pla and CO, although continuous measurement of AP and Pra is possible.
  • Diastolic pulmonary arterial pressure is used for continuously estimating Pla to obtain a continuous value.
  • Pla may be calculated from diastolic pulmonary arterial pressure based on an average correlation for multiple subjects. It is preferable to allow the average correlation (linear relationship) between diastolic pulmonary arterial pressure and Pla to be corrected according to heart rate, which causes a change in the correlation.
  • Diastolic time constant of peripheral arterial blood pressure waveform is used for estimating CO to obtain a continuous value.
  • CO may be, for example, calculated from diastolic time constant of peripheral arterial blood pressure waveform using a conventional method.
  • Target decision means (7) calculates target values of pumping ability (pumping ability of the left heart and/or the right heart), effective circulating blood volume, and vascular resistance. These target values are used as reference values by first to third comparison means (described below). Once target values of CO, Pla, Pra, and AP are input, target decision means (7) automatically figures out the target values of pumping ability (pumping ability of the left heart and/or the right heart), effective circulating blood volume, and vascular resistance. It is also possible for a user to input in advance these target values of pumping ability (pumping ability of the left heart and/or the right heart), effective circulating blood volume, and vascular resistance to the respective comparison means.
  • Target decision means (7) includes a first target decision means (71), a second target decision means (72), and a third target decision means (73).
  • First to third target decision means (71-73) are processing units configured to calculate output values according to input values.
  • Target decision means (7) may be a single processing unit that plays roles of first to third target decision means (71-73) in performing computations.
  • target decision means (7) may include three processing units respectively play roles of first to third target decision means (71-73) in performing computations.
  • First target decision means (71) calculates a target pumping ability value of the left heart from the target values of CO and Pla, and/or calculates a target pumping ability value of the right heart from the target values of CO and Pra.
  • First target decision means (71) may be configured to calculate both or either of the above-mentioned target pumping ability value of the left heart and/or the right heart.
  • a target CO value and a target Pla value are substituted in the following Equation 9 to figure out the target pumping ability value of the left heart value.
  • First target decision means (71) calculates a target right function value using the following Equation 10 by a similar calculation to the above-described calculation of the target pumping ability value of the left heart.
  • the target pumping ability value of the right heart is calculated by substituting the target CO value and the target Pra value in Equation 10.
  • Target decision means (7) includes second target decision means (72), as described above.
  • Second target decision means (72) calculates a target effective circulating blood volume value from the target CO value, the target Pla value, and the target Pra value.
  • the target CO value, the target Pla value, and the target Pra value are substituted in the following Equation 11 to figure out the target effective circulating blood volume value.
  • Equation 11 constants E, F, and G are user preset values that are adjustable for each patient. Adjustment of these values for each patient allows the calculated effective circulating blood volume value to be corrected.
  • target effective circulating blood volume value ⁇ ( target CO value ) + F ( target . Pra value ) + G target Pla value ⁇ ⁇ E where all of E ⁇ F ⁇ and G are constants
  • Target decision means (7) includes third target decision means (73), as described above.
  • Third target decision means (73) calculates a target vascular resistance value from the target CO value, the target Pra value, and the target AP value.
  • target CO value ( target arterial blood pressure value ) - ( target Pra value ) - H target CO value /
  • target values of CO, Pla, Pra, and AP are input to target decision means (7) by a user to obtain a desired patient condition.
  • Calculation means (3) carries out computation using the hemodynamic values input from input means (2).
  • Calculation means (3) includes a first calculation means (31), a second calculation means (32), and a third calculation means (33).
  • Computation means (3) may be a single processing unit that plays roles of first to third calculation means (31-33) in performing computations.
  • calculation means (3) may include three processing units that respectively play roles of first to third calculation means (31-33) in performing computation.
  • First calculation means (31) calculates a pumping ability value of the left heart from the CO value and the Pla value input from input means (2). Alternatively, first calculation means (31) calculates a target pumping ability value of the right heart from the CO value and the Pra value input from input means (2). First calculation means (31) may be configured to calculate both or either of the above-mentioned pumping ability value of the left heart and/or the right heart.
  • Equation 13 constants A and B are user preset values that are adjustable for each patient. Adjustment of these values for each patient allows the calculated pumping ability value of the left heart to be corrected.
  • CO value pumping ability value of the left heart ⁇ Log ⁇ Pla value - A + B ⁇ where both A and B are constants
  • Equation 14 the equation is converted into an equation such as Equation 14 shown below to allow the pumping ability value of the left heart to be calculated from the input values sent from input means (2).
  • Pumping ability value of the left heart CO value ⁇ Log ( ( Pla value ) - A ) + B ⁇ where both A and B are constants /
  • First calculation means (31) calculates a pumping ability value of the right heart using the following Equation 15 by a similar calculation to the above-described calculation of the pumping ability value of the left heart.
  • the pumping ability value of the right heart is calculated by substituting the CO value and the Pra value in Equation 15.
  • First calculation means 31 is provided with Equation 16 converted from Equation 15 to allow the pumping ability value of the right heart to be calculated from the values input from input means (2).
  • C and D are user preset values that are adjustable for each patient. Adjustment of these values for each patient allows the calculated pumping ability value of the right heart to be corrected.
  • the pumping ability value of the left heart and the pumping ability value of the right heart are both calculated by first calculation means (31) using the CO value, thus it is possible to show the pumping ability value of the left heart and the pumping ability value of the right heart by plotting the relationship among CO value, Pla value and Pra value using three axes for these, as shown in Fig. 3 .
  • the change in CO is represented as CO curve in the three dimensional coordinate.
  • the CO curve visualizes the integrated pumping ability of the left heart and the right heart so as to significantly facilitate the diagnosis on a patient.
  • Fig. 3 shows CO curve (a) of a normal heart and CO curve (b) of a failing heart.
  • the representation of a normal CO curve and a measured CO curve in one space facilitates the diagnosis.
  • Calculation means (3) includes second calculation means (32).
  • Second calculation means (32) calculates an effective circulating blood volume value from the CO value, the Pla value, and the Pra value.
  • Equation 17 constants E, F and G are user preset values that are adjustable for each patient. Adjustment of these values for each patient allows the calculated effective circulating blood volume value to be corrected.
  • CO value 1 E effective circulating blood volume value ⁇ F Pra value - G Pla value ⁇ where all of E , F , and G are constants
  • Equation 18 the equation is converted into an equation such as Equation 18 shown below to allow the effective circulating blood volume value to be calculated from the input values from input means (2).
  • Effective circulating blood volume value ⁇ ( CO value ) + F ( Pra value ) + G Pla value ⁇ ⁇ E where all of E ⁇ F ⁇ and G are constants
  • the CO value, the Pra value, and the Pla value used for calculation by second calculation means (32) can be plotted on three axes of a three dimensional coordinate.
  • the CO value, the Pla value, and the Pra value as three variables form a plane (venous return surface) as shown in Fig. 4 .
  • the venous return surface is defined by the three variables (CO value, Pla value, and Pra value) and constants E, F, and G.
  • the slope of the surface may be considered to be constant between different subjects or within a single subject. It is also possible to correct the slope for a particular group of patients.
  • the height of the venous return surface is determined by the calculated effective circulating blood volume value, where the slope is considered to be constant.
  • the effective circulating blood volume is represented in the venous return surface. This visualizes the effective circulating blood volume so as to significantly facilitate the diagnosis of a patient.
  • Fig. 4 shows venous return surface (c) of a normal subject and venous return surface (d) of a congestive patient where the effective circulating blood volume is increased.
  • Venous return surface (d) is upwardly shifted from venous return surface (c).
  • the representation of a normal venous surface and a measured venous surface in one space facilitates the diagnosis.
  • Calculation means (3) includes third calculation means (33).
  • Third calculation means (33) calculates a vascular resistance value from the CO value, the Pra value, and the AP value.
  • Constant H in Equation 19 is used to correct the non-linearity of vascular resistance. Adjustment of constant H helps to maintain the normal operation of the system even in a subject with a highly non-linear vascular resistance.
  • vascular resistance value ( arterial blood pressure value ) - ( Pra value ) - H CO value ⁇ where H is a constant /
  • Fig. 5 shows one embodiment of simultaneous representation of CO curve (e) and venous return surface (f) in a three dimensional coordinate diagram with three axes respectively plotting the CO value, the Pla value, and the Pra value.
  • a target point corresponding to the target value is defined in the three dimensional coordinate diagram. Until the target point coincides with the intersection point of CO curve (e) and venous return surface (f), the pumping abilities of the left heart and the right heart as represented in CO curve (e) and the effective circulating blood volume as represented in venous return surface are controlled by drug administration to the subject. This enables the CO value, the Pla value, and the Pra value to achieve the normal target values.
  • Comparison means (4) compares the values calculated in calculation means (3) and the target values of pumping ability (pumping ability of the left heart and/or the right heart), effective circulating blood volume, and vascular resistance calculated in target decision means (7).
  • Comparison means (4) includes a first comparison means (41), a second comparison means (42), and a third comparison means (43).
  • First comparison means (41) compares the pumping ability value of the left heart and /or the pumping ability value of the right heart calculated in first calculation means (31) and the target pumping ability value of the left heart value and/or the target pumping ability value of the right heart calculated in first target decision means (71). More specifically, after first calculation means (31) calculates the pumping ability value of the left heart, first comparison means (41) compares the calculated pumping ability value of the left heart and the target pumping ability value of the left heart calculated in first target decision means (71), and then sends dosing means (5) a signal indicating the result of the comparison.
  • first comparison means (41) finds out that the calculated pumping ability value of the left heart is larger than, equal to, or smaller than the target pumping ability value of the left heart. According to this comparison result, first comparison means (41) sends the dosing means (first dosing means (51)) described below a signal indicating that the calculated pumping ability value of the left heart is larger than (signal "large”), equal to (signal "equal”), or smaller than (signal "small”) the target pumping ability value of the left heart. In addition to one of signal "large”, signal “equal”, and signal “small”, first comparison means (41) may send the dosing means a signal indicating the quantified difference between the calculated pumping ability value of the left heart and the target pumping ability value of the left heart.
  • the target pumping ability value of the left heart may be set by a user as a default value, as described above.
  • the pumping ability value of the left heart has been described above, the pumping ability value of the right heart may be set in a similar way to the pumping ability value of the left heart. It is possible to use the pumping ability value of either the left heart or the right heart because they may exhibit an identical change (behavior).
  • Second comparison means (42) compares the effective circulating blood volume value calculated in second calculation means (32) and the target effective circulating blood volume value calculated in second target decision means (72). More specifically, after second calculation means (32) calculates the effective circulating blood volume value, second comparison means (42) compares the calculated effective circulating blood volume value and the target effective circulating blood volume value calculated in second target decision means (72), and then sends dosing means (5) a signal indicating the result of the comparison.
  • second comparison means (42) finds out that the calculated effective circulating blood volume value is larger than, equal to, or smaller than the target effective circulating blood volume value. According to this comparison result, second comparison means (42) sends the dosing means (second dosing means (52)) described below a signal indicating that the calculated effective circulating blood volume value is larger than (signal "large”), equal to (signal "equal”), or smaller than (signal "small”) the target effective circulating blood volume value. In addition to one of signal "large”, signal “equal”, and signal “small”, second comparison means (42) may send the dosing means a signal indicating the quantified difference between the calculated effective circulating blood volume value and the target effective circulating blood volume value.
  • the target effective circulating blood volume value may be set by a user as a default value, as described above.
  • Third comparison means (43) compares the vascular resistance value calculated in third calculation means (33) and the target vascular resistance value calculated in third target decision means (73). More specifically, after third calculation means (33) calculates the vascular resistance value, third comparison means (43) compares the calculated vascular resistance value and the target vascular resistance value calculated in third target decision means (73), and then sends dosing means (5) a signal indicating the result of the comparison.
  • third comparison means (43) finds out that the calculated vascular resistance value is larger than, equal to, or smaller than the target vascular resistance value. According to this comparison result, third comparison means (43) sends the dosing means (third dosing means (53)) described below a signal indicating that the calculated vascular resistance value is larger than (signal "large”), equal to (signal "equal”), or smaller than (signal "small”) the target vascular resistance value. In addition to one of signal “large”, signal “equal”, and signal “small”, third comparison means (43) may send the dosing means a signal indicating the quantified difference between the calculated vascular resistance value and the target vascular resistance value.
  • the target vascular resistance value may be set by a user as a default value, as described above.
  • Dosing means (5) receives the comparison results from comparison means (4) to start and/or stop drug administration to a patient according to the comparison results.
  • Dosing means (5) includes a first dosing means (51), a second dosing means (52), and a third dosing means (53).
  • First to third dosing means (51-53) are configured to administer drugs to a patient, as described below, and to control the drug administration (adjust the amount of drugs to be administered) to a patient using the signals sent by comparison means (4) according to the comparison results.
  • Dosing means (5) may be, for example, a multilumen type catheter for simultaneous infusion of multiple drugs that is connected to multiple automatic infusion pumps.
  • the catheter is placed in the vein of a patient for intravenous administration of drugs.
  • First dosing means (51) administers a certain drug into the body of the patient according to the signal of the comparison results sent from first comparison means (41).
  • the drug administration according to the signal of the comparison results from first comparison means (41) allows first dosing means (51) to start drug administration when abnormal pumping ability is detected.
  • first dosing means (51) receives a signal "small” (a signal sent when the calculated pumping ability value of the left heart is smaller than the target pumping ability value) from first comparison means (41). Since the signal indicates abnormal pumping ability, first dosing means (51) starts drug administration to improve pumping ability. Inotropic agent such as dobutamine and dopamine is administered in this drug administration.
  • first dosing means (51) receives a signal "equal" (a signal sent when the calculated pumping ability value of the left heart is equal to the target pumping ability value) from first comparison means (41). Since the signal indicates normal pumping ability, first dosing means (51) responds by not increasing the dose of the drug, by administering no drug, or by stopping administration of the drug.
  • first dosing means (51) receives a signal "large” (a signal sent when the calculated pumping ability value of the left heart is larger than the target pumping ability value) from first comparison means (41). Since the signal indicates better pumping ability than targeted, first dosing means (51) responds by reducing the dose of the inotropic agent, or by not administering the inotropic agent, or by stopping administration of the inotropic agent.
  • the dose of the drugs administered by first dosing means (51) is not particularly limited but an appropriate dose for a patient is primarily selected. It is possible to vary the dose based on the difference between the calculated pumping ability value and the target pumping ability value, which are compared by first comparison means (41). Although, in the above description, the operation of first dosing means (51) is controlled by the signals obtained by dividing calculated pumping ability values into three levels according to whether the calculated pumping ability value is larger than, equal to, smaller than the target pumping ability value, it is also possible to divide the calculated pumping ability values into multiple levels according to the deviation from the target pumping ability value and then to vary the dose of drugs. The variation of dose according to the multiple levels results in highly accurate administration of the drugs.
  • Second dosing means (52) administers a certain drug into the body of the patient according to the signal of the comparison results sent from second comparison means (42).
  • the drug administration according to the signal of the comparison results from second comparison means (42) allows second dosing means (52) to start drug administration when abnormal effective circulating blood volume is detected.
  • second dosing means (52) receives a signal "large” (a signal sent when the calculated effective circulating blood volume value is larger than the target effective circulating blood volume value) from second comparison means (42). Since the signal indicates abnormal effective circulating blood volume, second dosing means (52) starts drug administration to reduce effective circulating blood volume. Diuretic such as furosemide is administered in this drug administration.
  • second dosing means (52) receives a signal "equal" (a signal sent when the calculated effective circulating blood volume value is equal to the target effective circulating blood volume value) from second comparison means (42). Since the signal indicates normal effective circulating blood volume, second dosing means (52) responds by administering no drug or by stopping administration of the drug.
  • a signal "equal" a signal sent when the calculated effective circulating blood volume value is equal to the target effective circulating blood volume value
  • second dosing means (52) receives a signal "small” (a signal sent when the calculated effective circulating blood volume value is smaller than the target effective circulating blood volume value) from second comparison means (42). Since the signal indicates abnormal effective circulating blood volume, second dosing means (52) starts drug administration to increase effective circulating blood volume. Infusion of a drug for increasing effective circulating blood volume such as low molecular dextran or albumin preparation is administered in this drug administration.
  • the dose of the drugs administered by second dosing means (52) is not particularly limited but an appropriate dose for a patient is primarily selected, as described for first dosing means (51). It is possible to vary the dose based on the difference between the calculated effective circulating blood volume value and the target effective circulating blood volume value, which are compared by second comparison means (42). Specifically, the calculated effective circulating blood volume values are divided into multiple levels according to the deviation from the target effective circulating blood volume value and then the dose of drugs is varied according to the levels. The variation of dose according to the multiple levels results in highly accurate administration of the drugs.
  • Third dosing means (53) administers a certain drug into the body of the patient according to the signal of the comparison results sent from third comparison means (43).
  • third comparison means (43) allows third dosing means (53) to start drug administration when abnormal vascular resistance is detected.
  • third dosing means (53) receives a signal "large” (a signal sent when the calculated vascular resistance value is larger than the target vascular resistance value) from third comparison means (43). Since the signal indicates abnormal vascular resistance, third dosing means (53) starts drug administration to reduce vascular resistance.
  • Vasodilator such as nitroprusside, nitroglycerin, and phentolamine is administered in this drug administration. If vasoconstrictor such as norepinephrine has been already administered, the dose of the vasoconstrictor is reduced.
  • third dosing means (53) receives a signal "equal" (a signal sent when the calculated vascular resistance value is equal to the target vascular resistance value) from third comparison means (43). Since the signal indicates normal vascular resistance, third dosing means (53) responds by administering no drug or by stopping administration of the drug.
  • third dosing means (53) receives a signal "small” (a signal sent when the calculated vascular resistance value is smaller than the target vascular resistance value) from third comparison means (43). Since the signal indicates abnormal vascular resistance value, third dosing means (53) starts drug administration to increase vascular resistance. Vasoconstrictor such as norepinephrine is administered in this drug administration. If vasodilator such as nitroprusside, nitroglycerin, and phentolamine has been already administered, the dose of the vasodilator is reduced.
  • the dose of the drugs administered by third dosing means (53) is not particularly limited but an appropriate dose for a patient is primarily selected, as described for the first dosing means (51). It is possible to vary the dose based on the difference between the calculated vascular resistance value and the target vascular resistance value, which are compared by third comparison means (43). Specifically, the calculated effective circulating blood volume values are divided into multiple levels according to the deviation from the target effective circulating blood volume value and then the dose of drugs is varied according to the levels. The variation of dose according to the multiple levels results in highly accurate administration of the drugs.
  • first to third dosing means may be configured to use time-based control to achieve the target values of pumping ability, effective circulating blood volume, and vascular resistance, which are determined by first to third comparison means (41-43).
  • PI Proportional Integral
  • PID Propotional Integral Derivative
  • the PI control and PID control on the dose of drugs results in highly accurate administration.
  • adaptive control is used in adjusting the dose of drugs.
  • Display means (6) is an output device that displays the input values of CO, Pla, Pra, and AP input by input means (2) as well as the calculated values obtained by the above-described first to third calculation means (31-33).
  • Display means (6) displays the calculated values of pumping ability, effective circulating blood volume, and vascular resistance, which are calculated in each calculation means (31-33), preferably in a continuous time-series line plot because each calculation means (31-33) continuously obtains calculated values from the input values obtained in the above-described continuous measurement of patient conditions by cardiac disease treatment system (1).
  • the continuous time-series line plot visualizes a time-series change and makes the change easily noticed.
  • Display means (6) is preferably configured to display the dose of drugs administered by first to third dosing means (51-53).
  • the additional display of the drug dose effectively allows a user to observe the change (transition) in pumping ability, effective circulating blood volume, and vascular resistance of a patient simultaneously with the dose of drugs.
  • cardiac disease treatment system (1) The configurations of cardiac disease treatment system (1) according to the present invention have been described thus far.
  • cardiac disease treatment system (1) The operation of cardiac disease treatment system (1) according to the present invention will be described below.
  • Fig. 6 is a flow chart illustrating the use of the cardiac disease treatment system according to the present invention.
  • cardiac disease treatment system (1) needs preset constants A to G in a practical use, description of these constants is omitted here.
  • Target values of CO, Pra, Pla, and AP used by first to third target decision means (71-73) of target decision means (7) are set by a user to a certain value in the following example.
  • a user inputs target values of CO, Pra, Pla, and AP which represent desired patient conditions.
  • target decision means (7) calculates target values of pumping ability of the left heart, pumping ability of the right heart, effective circulating blood value, and vascular resistance.
  • first decision means (71) calculates target left function value.
  • target CO value and the target Pra value are input to first target decision means (71) it calculates a target pumping ability value of the right heart (S01).
  • target CO value the target CO value
  • target Pla value the target Pla value
  • target Pra value the target effective circulating blood volume value
  • target CO value, the target Pra value, and the target AP value are input to third target decision means (73), it calculates a target vascular resistance value (S03).
  • target decision means (7) After respective target values of pumping ability of the left heart, pumping ability of the right heart, effective circulating blood volume, and vascular resistance are calculated by target decision means (7), these target values are sent to display means (6).
  • the target values sent to display means (6) are respectively displayed in continuous time-series line plot (see S5 described below).
  • a Swan-Ganz catheter is connected to a patient in this measurement, although other apparatus may be used.
  • the measurement values of AP, CO, Pra, and Pla are input by input means (2) to calculation means (3).
  • calculation means (3) calculates a pumping ability value of the left heart, a pumping ability value of the right heart, an effective circulating blood volume value, and a vascular resistance value. Specifically, once the CO value and the Pla value are input to first calculation means, it calculates a pumping ability value of the left heart. In addition, once CO value and Pra value are input to first calculation means (31), it calculates a right function value (S2).
  • first to third calculation means respectively calculate a pumping ability value of the left heart, a pumping ability value of the right heart, an effective circulating blood volume value, and a vascular resistance value.
  • first comparison means (41) receives the target pumping ability value of the left heart calculated in first target decision means (71).
  • First comparison means (41) compares the pumping ability value of the left heart (or the pumping ability value of the right heart) with the target pumping ability value of the left heart (or the target pumping ability value of the right heart) (S6).
  • First comparison means (41) sends first dosing means (51) the results of comparison between the calculated pumping ability value of the left heart and the target pumping ability value of the left heart.
  • the effective circulating blood volume value calculated in second calculation means (32) is sent to second comparison means (42).
  • second comparison means (42) receives the target effective circulating blood volume value calculated in second target decision means (72).
  • Second comparison means (42) compares the effective circulating blood volume value with the target effective circulating blood volume value (S7).
  • Second comparison means (42) sends second dosing means (52) the results of comparison between the calculated effective circulating blood volume value and the target effective circulating blood volume value.
  • third comparison means (43) receives the target vascular resistance value calculated in third target decision means (73). Third comparison means (43) compares the vascular resistance value and the target vascular resistance value (S8).
  • Third comparison means (43) sends third dosing means (53) the results of comparison between the calculated vascular resistance value and the target vascular resistance value.
  • First dosing means (51) receives the comparison result obtained in first comparison means (41) and then administers drugs according to this comparison result (S9).
  • first dosing means (51) administers inotropic agent to a patient to increase the pumping ability value of the patient.
  • first comparison means (41) If the comparison result from first comparison means (41) shows that first dosing means (51) should stop drug administration or should administer no drug (if the calculated pumping ability value is equal to the target pumping ability value), first dosing means (51) stops drug administration or continues with no drug administration.
  • first dosing means (51) If the comparison result from first comparison means (41) shows that first dosing means (51) should administer no drug (if the calculated pumping ability value is larger than the target pumping ability value), first dosing means (51) reduces the dose of inotropic agent, or stops administration of inotropic agent, or continues with no administration of inotropic agent.
  • Second dosing means (52) receives the comparison result obtained in second comparison means (42) and then administers drugs according to this comparison result (S10).
  • second dosing means (51) If the comparison result from second comparison means (42) shows that second dosing means (51) should promote drug administration (if the calculated effective circulating blood volume value is smaller than the target effective circulating blood volume value), second dosing means (52) responds by administering an appropriate infusion of drugs such as low molecular dextran and albumin preparation to a patient to increase the effective circulating blood volume value of the patient.
  • drugs such as low molecular dextran and albumin preparation
  • second dosing means (52) If the comparison result from second comparison means (42) shows that second dosing means (52) should stop drug administration or should administer no drug (if the calculated effective circulating blood volume value is equal to the target effective circulating blood volume value), second dosing means (52) stops drug administration or continues with no drug administration.
  • second dosing means (52) administers diuretic to a patient to reduce effective circulating blood volume of the patient.
  • Third dosing means (53) receives the comparison result obtained in third comparison means (43) and then administers drugs according to this comparison result (S11).
  • third dosing means (53) administers vasoconstrictor to a patient to increase the vascular resistance value of the patient.
  • third dosing means (53) stops drug administration or continues with no drug administration.
  • third dosing means (53) administers vasodilator to a patient to reduce the vascular resistance of the patient.
  • first to third dosing means (51-53) may use a multi-level control or a real time control (PI control, PID control, or the like) on the dose.
  • First to third dosing means (51-53) may use an adaptive control on the dose for patients who manifest an idiosyncratic response to drugs.
  • Display means (6) displays the time sequence of the pumping ability values (pumping ability value of the left heart and pumping ability value of the right heart), the effective circulating blood volume value, and the vascular resistance value, each calculated by first to third calculation means (31-33); the target values of pumping ability (pumping ability of the left heart and pumping ability of the right heart), effective circulating blood volume, and vascular resistance, each calculated by first to third target decision means (71-73); and the dose of drugs administered according to these calculated values (S12).
  • the display of these calculated values, target values, and the dose of drugs by display means (6) allows a user of cardiac disease treatment system (1) to carry out real time diagnosis on patient conditions.
  • Constants C and D are obtained by linear regression to the measurement values listed in table 2 and a modification for the practical use.
  • Table 2 Dog Pumping ability of the right heart C D Coefficient of determination Standard error of estimate 1 46.7 2.12 2.34 0.98 4.7 2 33.9 1.50 2.50 0.96 3.3 3 64.1 2.10 2.10 0.90 8.2 4 112.7 1.39 0.19 0.98 5.5 5 101.8 1.39 0.92 0.99 4.6 6 80.6 3.07 1.59 0.99 2.8 7 37.1 3.33 3.69 0.94 6.8 Average 68.1 2.13 1.90 0.96 5.1 Standard Deviation 31.3 0.80 1.14 1.9
  • cardiac disease treatment system (1) in the present invention was operated.
  • Figs. 7 and 8 show one example of the use of the cardiac disease treatment system according to the present invention.
  • Fig. 7 shows the chronological change in AP, right atrial pressure (Pra), left atrial pressure (Pla), and cardiac output (CO).
  • AP, Pra, Pla, and CO achieve target values within 20 minutes from the onset of treatment.
  • Fig. 8 shows a chronological change in effective circulating blood volume, pumping ability of the left heart, pumping ability of the right heart, vascular resistance, the dose of inotropic agent and vasodilator, and infusion amount.
  • inotropic agent and vasodilator dobutamine and nitroprusside are used respectively.
  • Low molecular dextran infusion is used.
  • PI control is used in determining the dose of inotropic agent and vasodilator while multi-level control is used in determining the infusion amount.
  • the effective circulating blood volume value is in excess of the target effective circulating blood volume value; the pumping ability value of the left heart and the pumping ability value of the right heart are lower than the target pumping ability value of the left heart and the target pumping ability value of the right heart; and the vascular resistance value is higher than the target vascular resistance value, as shown in Fig. 8 . All of these values are significantly different from the target values to be in an abnormal range (calculation means (3) calculates each of the effective circulating blood volume value, the left pumping ability value of the left heart, the pumping ability value of the right heart, and the vascular resistance value. Comparison means (4) determines the condition of these parameters (whether they are in a normal or abnormal range)).
  • dosing means (5) starts administering drugs to allow each calculated value to achieve each target value, according to the conditions (dosing means (5) administers an appropriate dose of drugs). The above-described processes are repeated until the respective calculated values achieve the target values.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Physiology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • External Artificial Organs (AREA)
  • Electrotherapy Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Surgical Instruments (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP04822649A 2004-11-18 2004-11-18 System zur behandlung von herzkrankheiten Not-in-force EP2020248B1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2004/017154 WO2006054343A1 (ja) 2004-11-18 2004-11-18 心疾患治療システム

Publications (3)

Publication Number Publication Date
EP2020248A1 true EP2020248A1 (de) 2009-02-04
EP2020248A4 EP2020248A4 (de) 2009-02-11
EP2020248B1 EP2020248B1 (de) 2011-03-30

Family

ID=36406891

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04822649A Not-in-force EP2020248B1 (de) 2004-11-18 2004-11-18 System zur behandlung von herzkrankheiten

Country Status (7)

Country Link
US (1) US8282563B2 (de)
EP (1) EP2020248B1 (de)
JP (1) JP4892667B2 (de)
CN (1) CN101107024B (de)
AT (1) ATE503510T1 (de)
DE (1) DE602004032070D1 (de)
WO (1) WO2006054343A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102014010406B3 (de) * 2014-07-15 2015-01-08 Tricumed Medizintechnik Gmbh Defibrillationsinfusionspumpe
US11540731B2 (en) 2018-12-21 2023-01-03 W. L. Gore & Associates, Inc. Medical treatment system using measurement data from multiple sensors

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8282563B2 (en) 2004-11-18 2012-10-09 Japan Health Sciences Foundation Cardiac disease treatment system
EP2442711B1 (de) * 2009-06-17 2024-02-21 Human Chimp Pty Ltd Bestimmung der hämodynamischen leistung
CN109414534B (zh) * 2016-07-01 2021-07-06 心脏器械股份有限公司 用于维持流体平衡的系统和方法
FR3070250B1 (fr) * 2017-08-30 2022-04-22 Inria Inst Nat Rech Informatique & Automatique Dispositif cardiaque

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0297675A1 (de) * 1987-06-30 1989-01-04 Stichting Foundation For The Administration Of Patent Rights Of Dr. H. Goslinga Et Al Ballonkatheter zur Ausführung von Blutdynamik-Messungen an Patienten
US5368040A (en) * 1993-08-02 1994-11-29 Medtronic, Inc. Apparatus and method for determining a plurality of hemodynamic variables from a single, chroniclaly implanted absolute pressure sensor
US20030149450A1 (en) * 2002-02-01 2003-08-07 Mayberg Marc R. Brainstem and cerebellar modulation of cardiovascular response and disease
US20030199813A1 (en) * 2002-04-22 2003-10-23 Struble Chester L. Implantable drug delivery system responsive to intra-cardiac pressure

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4269193A (en) * 1977-11-04 1981-05-26 Sri International Noninvasive blood pressure monitoring transducer
JPH01305962A (ja) * 1988-06-03 1989-12-11 Nec Corp 点滴制御装置
US4943279A (en) * 1988-09-30 1990-07-24 C. R. Bard, Inc. Medical pump with infusion controlled by a detachable coded label
ES2098333T3 (es) * 1991-01-31 1997-05-01 Baxter Int Bomba de instilacion automatica con cartuchos de memoria sustituibles.
US5289823A (en) * 1992-05-12 1994-03-01 Colin Electronics Co., Ltd. Non-invasive aortic blood flow sensor and method for non-invasively measuring aortic blood flow
DE4320365C2 (de) * 1993-06-19 2000-07-13 Uvo Hoelscher Mehrkanal-Dosiersystem
US5687733A (en) * 1995-10-26 1997-11-18 Baxter International Inc. System and method for estimating cardiac output
BE1010264A5 (nl) * 1996-03-18 1998-04-07 Struys Michel Inrichting voor het controleren van een intraveneuze injectie.
US6292689B1 (en) * 1996-04-17 2001-09-18 Imagyn Medical Technologies California, Inc. Apparatus and methods of bioelectrical impedance analysis of blood flow
US6090047A (en) * 1996-11-04 2000-07-18 Johns Hopkins University, School Of Medicine Assessing cardiac contractility and cardiovascular interaction
US6149595A (en) * 1998-07-02 2000-11-21 Seitz; Walter S. Noninvasive apparatus and method for the determination of cardiac valve function
US6371923B1 (en) * 1999-12-07 2002-04-16 Edwards Lifesciences Corporation Time-domain system and method for relaxation measurement and estimation of indicator dilution for continuous estimation and display of cardiac ejection fraction and end diastolic volume
JP2003527186A (ja) * 2000-03-17 2003-09-16 メドトロニック・インコーポレーテッド 患者管理システム用の心不全モニタのクイックルック概要
US6527698B1 (en) * 2000-05-30 2003-03-04 Abiomed, Inc. Active left-right flow control in a two chamber cardiac prosthesis
US6540658B1 (en) * 2000-05-30 2003-04-01 Abiomed, Inc. Left-right flow control algorithm in a two chamber cardiac prosthesis
JP3400417B2 (ja) * 2000-08-11 2003-04-28 日本コーリン株式会社 中枢動脈圧波形推定装置
WO2002078539A1 (en) * 2001-04-02 2002-10-10 N.I. Medical Ltd. Device for determining hemodynamic state
US20020161304A1 (en) * 2001-04-30 2002-10-31 Eide Per Kristian Monitoring pressure in a body cavity
GB0121054D0 (en) * 2001-08-30 2001-10-24 Monitoring Tech Ltd A method for the measurement of post arteriolar pressure
US7500949B2 (en) * 2002-03-01 2009-03-10 Medtronic Minimed, Inc. Multilumen catheter
US7024244B2 (en) * 2002-04-22 2006-04-04 Medtronic, Inc. Estimation of stroke volume cardiac output using an intracardiac pressure sensor
US7862513B2 (en) * 2002-05-14 2011-01-04 Pacesetter, Inc. Apparatus for minimally invasive calibration of implanted pressure transducers
US7494459B2 (en) * 2003-06-26 2009-02-24 Biophan Technologies, Inc. Sensor-equipped and algorithm-controlled direct mechanical ventricular assist device
US7220230B2 (en) * 2003-12-05 2007-05-22 Edwards Lifesciences Corporation Pressure-based system and method for determining cardiac stroke volume
US7452333B2 (en) * 2003-12-05 2008-11-18 Edwards Lifesciences Corporation Arterial pressure-based, automatic determination of a cardiovascular parameter
US8282563B2 (en) 2004-11-18 2012-10-09 Japan Health Sciences Foundation Cardiac disease treatment system
US7666144B2 (en) * 2006-02-21 2010-02-23 Board Of Trustees Operating Michigan State University Methods and apparatus for determining cardiac output and left atrial pressure

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0297675A1 (de) * 1987-06-30 1989-01-04 Stichting Foundation For The Administration Of Patent Rights Of Dr. H. Goslinga Et Al Ballonkatheter zur Ausführung von Blutdynamik-Messungen an Patienten
US5368040A (en) * 1993-08-02 1994-11-29 Medtronic, Inc. Apparatus and method for determining a plurality of hemodynamic variables from a single, chroniclaly implanted absolute pressure sensor
US20030149450A1 (en) * 2002-02-01 2003-08-07 Mayberg Marc R. Brainstem and cerebellar modulation of cardiovascular response and disease
US20030199813A1 (en) * 2002-04-22 2003-10-23 Struble Chester L. Implantable drug delivery system responsive to intra-cardiac pressure

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2006054343A1 *
UEMURA, SUGIMACHI, KAWADA, KAMIYA, JIN, KASHIHARA, SUNAGAWA: "A novel framework of circulatory equilibrium" AM J PHYSIOL HEART CIRC PHYSIOL, vol. 286, no. 6, 5 February 2004 (2004-02-05), pages H2376-H2385, XP002507894 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102014010406B3 (de) * 2014-07-15 2015-01-08 Tricumed Medizintechnik Gmbh Defibrillationsinfusionspumpe
US11540731B2 (en) 2018-12-21 2023-01-03 W. L. Gore & Associates, Inc. Medical treatment system using measurement data from multiple sensors
US11911135B2 (en) 2018-12-21 2024-02-27 W. L. Gore & Associates, Inc. Implantable medical device with adjustable blood flow

Also Published As

Publication number Publication date
CN101107024A (zh) 2008-01-16
US8282563B2 (en) 2012-10-09
ATE503510T1 (de) 2011-04-15
JP4892667B2 (ja) 2012-03-07
JPWO2006054343A1 (ja) 2008-05-29
EP2020248B1 (de) 2011-03-30
WO2006054343A1 (ja) 2006-05-26
EP2020248A4 (de) 2009-02-11
CN101107024B (zh) 2010-08-11
US20090221923A1 (en) 2009-09-03
DE602004032070D1 (de) 2011-05-12

Similar Documents

Publication Publication Date Title
US8128570B2 (en) Personalized fluid assessment
EP2197521B1 (de) Computergesteuertes system zur regelung des blutglucosespiegels
JP2001204817A (ja) グルコース濃度の外挿システム
EP2131897B1 (de) Gerät zur infusion von mindestens zwei medikamenten
US20030036744A1 (en) System and method for adaptive drug delivery
US20070282299A1 (en) Method and Device for Calculating a Bolus Amount
US20120130697A1 (en) Determining hemodynamic performance
EP4026490B1 (de) Verfahren und vorrichtung zur vorhersage des ansprechens von mechanisch beatmeten personen auf eine flüssigkeit
JP2013078579A (ja) 血行動態モニタリング装置
US11167084B2 (en) Control device for controlling the administration of propofol to a patient
Sng et al. Assessment of an updated double‐vasopressor automated system using Nexfin™ for the maintenance of haemodynamic stability to improve peri‐operative outcome during spinal anaesthesia for caesarean section
Oei-Lim et al. Pharmacokinetics of propofol during conscious sedation using target-controlled infusion in anxious patients undergoing dental treatment.
US20140046153A1 (en) Monitoring volaemic condition in a human or animal subject
JP4581050B2 (ja) 心臓酸素消費量自動最小化システムおよびこれを用いた心疾患治療システム
EP2020248B1 (de) System zur behandlung von herzkrankheiten
JP2007215724A5 (de)
Valverde et al. Comparison of cardiac output determined by arterial pulse pressure waveform analysis method (FloTrac/Vigileo) versus lithium dilution method in anesthetized dogs
RU2373960C2 (ru) Система для лечения заболеваний сердца
KR20170056904A (ko) 연속 혈당 감지를 이용한 인슐린 투여 시스템
US20100137789A1 (en) Drug delivery presentation and arrangement for drug delivery presentation
AU2014250646B2 (en) Determining haemodynamic performance
EP4335360A1 (de) Nichtinvasive blutdruckmessung
JPH08227312A (ja) 測定間隔自動制御装置
Wakeland et al. Estimation of subject-specific ICP dynamics models using prospective clinical data
Gupta-Malhotra et al. Ambulatory Blood Pressure in Children and Adolescents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070618

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20090112

R17P Request for examination filed (corrected)

Effective date: 20070618

17Q First examination report despatched

Effective date: 20091222

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602004032070

Country of ref document: DE

Date of ref document: 20110512

Kind code of ref document: P

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602004032070

Country of ref document: DE

Effective date: 20110512

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20110330

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110701

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110801

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110711

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110730

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

26N No opposition filed

Effective date: 20120102

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602004032070

Country of ref document: DE

Effective date: 20120102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111130

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111130

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111130

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20191023

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20191104

Year of fee payment: 16

Ref country code: FR

Payment date: 20191028

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20191004

Year of fee payment: 16

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602004032070

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20201118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201130

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201118

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210601